Leamon Christopher's most recent trade in Fusion Pharmaceuticals Inc was a trade of 106,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 31, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fusion Pharmaceuticals Inc | Leamon Christopher | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2023 | 106,100 | 106,100 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Christopher Leamon | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2023 | 63,700 | 63,700 | - | - | Restricted Stock Units | |
| Fusion Pharmaceuticals Inc | Christopher Leamon | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2023 | 11,957 | 11,957 | - | - | Common Stock | |
| Fusion Pharmaceuticals Inc | Christopher Leamon | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Christopher Leamon | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 218,000 | 218,000 | - | - | Stock Option (Right to Buy) |